$1.70
1.19% today
Nasdaq, Feb 05, 04:15 pm CET
ISIN
CA29668H7085
Symbol
EPIX
Sector
Industry

ESSA Pharma Inc Stock price

$1.68
-0.24 12.50% 1M
-2.95 63.71% 6M
-0.11 6.15% YTD
-8.33 83.22% 1Y
-8.37 83.28% 3Y
-3.83 69.51% 5Y
-86.63 98.10% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.01 0.59%
ISIN
CA29668H7085
Symbol
EPIX
Sector
Industry

Key metrics

Market capitalization $74.54m
Enterprise Value $-51.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.29
P/B ratio (TTM) P/B ratio 0.60
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-34.42m
Free Cash Flow (TTM) Free Cash Flow $-22.66m
Cash position $126.76m
EPS (TTM) EPS $-0.64
P/E forward negative
Short interest 2.59%
Show more

Is ESSA Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

ESSA Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ESSA Pharma Inc forecast:

4x Hold
100%

Analyst Opinions

4 Analysts have issued a ESSA Pharma Inc forecast:

Hold
100%

Financial data from ESSA Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.09 0.09
25% 25%
-
-0.09 -0.09
25% 25%
-
- Selling and Administrative Expenses 13 13
23% 23%
-
- Research and Development Expense 21 21
1% 1%
-
-34 -34
7% 7%
-
- Depreciation and Amortization 0.09 0.09
25% 25%
-
EBIT (Operating Income) EBIT -34 -34
7% 7%
-
Net Profit -29 -29
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about ESSA Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ESSA Pharma Inc Stock News

Neutral
GlobeNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
2 days ago
NEW YORK , Feb. 3, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Neutral
PRNewsWire
3 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-9...
More ESSA Pharma Inc News

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Head office Canada
CEO David Parkinson
Employees 35
Founded 2009
Website www.essapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today